N/A N=98 Fully Covered or Partially Covered Stents in Malignant Esophageal Strictures
Esophageal Cancer · Esophageal Stenosis
Primary: Number of Participants With Recurrent Dysphagia. — 11; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Outcomes of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management
Esophageal Dilation · Refractory Benign Esophageal Stricture
Primary: Number of Endoscopic Interventions — 12; 11; 12; 7 endoscopies
N/A N=1 Esophageal Fully Covered Metal Stents in Caustic Strictures Study
Refractory Benign Esophageal Strictures Caused by Caustic Ingestion
Primary: Clinical Success — 1 Participants
N/A N=18 WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture
Refractory Anastomotic Esophageal Strictures
Primary: Number of Dilation Procedures — 5.4; 2.4 Dilation procedures — p=0.159
Phase 2 N=90 Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy
Esophageal Stricture
Primary: Dysplasia in Barrett Esophagus (BE) — 4; 4; 3; 23 Participants — p=0.992
N/A N=96 Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Primary: Complete Response — 81 Participants
N/A N=7 Endoesophageal Brachytherapy for Patients With Esophageal Cancer
Esophageal Cancer
Primary: Dose of Radiation Delivered to 90% of Tumor Volume (D90) — 105.5 percentage of Prescription dose
N/A N=112 Covered Metallic Stents for First-Line Treatment of Benign Bile Duct Strictures
Common Bile Duct Stricture
Primary: Early Clinical Success — 50; 41 Participants
N/A N=17 Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction
Duodenal Obstruction
Primary: Number of Participants With Any Change (2 Point Increase or Decrease) in Symptoms From Baseline — 7; 6 Participants
Phase 2 N=73 Endoscopic Therapy of Early Cancer in Barretts Esophagus
Early Stage Esophageal Adenocarcinoma · Barrett Esophagus
Primary: Level of Dysplasia on Histology at 12 Months — 10; 11; 15; 2 paricipants — p=0.0098
Phase 2 N=78 Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material
Esophageal Adenocarcinoma
Primary: Number of Participants With Anastomotic Leak. — 10; 68 Participants
N/A N=50 Study of the Efficiency of Esophageal Dilation on Patient With Eosinophilic Esophagitis
Suspected Eosinophilic Esophagitis
Primary: Percent Change From Baseline in Dysphagia Score in Patients With Eosinophilic Esophagitis (EE) — 69; 79 Percent Change
Phase 2 N=4 Trimodality Management of T1b Esophageal Cancers
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
N/A N=60 EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX
Malignant Esophageal Strictures
Primary: Mellow and Pinkas Dysphagia Score at Baseline and 2 Weeks Following the Treatment — 0.6; 0.6 units on a scale
Phase 2 N=74 Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal Cancer
Primary: Rate of Participants Who Were Alive at 2 Years — 71; 53 percentage of participants
Phase 1 N=16 Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
Esophageal Cancer · Cancer of the Esophagus
Primary: Safety as Measured by Number of Participants With Grade 3 or Higher Treatment Related Adverse Events — 1; 1; 1; 1 Participants
N/A N=30 Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX
Esophageal Cancer
Primary: Anastomotic Leak Rate After Esophagectomy
N/A N=30 Mucosal Impedance and Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Esophageal Mucosal Impedance (MI) — 1457; 3463; 4225; 1713 Ohms
N/A N=63 Gastric Outlet Obstructions Tailored Covered Stents for GOO
Gastric Outlet Obstruction
Primary: Efficiency of Stents — 1; 7 participants
N/A N=24 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
Ureteral Obstruction
Primary: Mean Stent Dwell Time — 17; 3.97 months
N/A N=44 A Diagnostic Study of the Advanced Endoscopy to Detect Early Esophageal Cancer
Esophageal Neoplasms
Primary: Accuracy — 89; 70 Percentage of accuracy
Phase 2 N=69 Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
Esophageal Carcinoma
Primary: Median Recurrence Free Survival Time — 23.1 months
N/A N=6 Covered vs Uncovered Metal Stents for Palliative Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction
Distal Bile Duct Obstruction
Primary: Rate of Long-term Stent Failure — 0; 2 Participants
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
N/A N=31 Radiation Dose Escalation in Esophageal Cancer
Esophageal Cancer
Primary: Number of Dose Limiting Toxicities (DLTs) Occurring in Participants — 0; 0; 0; 1 dose limiting toxicity
N/A N=47 Esophageal Deviation in Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Number of Participants With a Minimum Distance of 1 cm Esophageal Deviation Between the Ablation Line for the Ipsilateral Pulmonary Vein (PV) Pairs and the Trailing Edge…
N/A N=93 Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment
Esophageal Lesion
Primary: Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy — 15 Participants
Phase 2 N=55 Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma
Esophageal Cancer
Primary: Number of Participants With Overall Response Rate (RR) — 44 participants
Phase 2 N=35 Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)
Locally Advanced Esophageal and Gastric Cancers (EGC)
Primary: Number of Participants With Pathologic Complete Response (pCR) — 11 Participants
N/A N=53 Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium
Barrett's Esophagus · Esophageal Squamous Dysplasia · Esophageal Cancer
Primary: Number of Participants With Complete Eradication of Esophageal Dysplasia — 51 Participants